|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,390 KRW | +0.37% |
|
-3.98% | -26.99% |
| 2023 | Vaxcell-Bio Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2021 | Vaxcell-Bio Therapeutics Co., Ltd.(KOSDAQ:A323990) added to S&P Global BMI Index | CI |
Vaxcell-Bio Therapeutics Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was KRW 2,242.69 million compared to KRW 1,685.22 million a year ago. Basic loss per share from continuing operations was KRW 147 compared to KRW 111 a year ago.
Basic loss per share was KRW 147 compared to KRW 111 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -26.99% | 272M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
VAXCELL-BIO THERAPEUTICS CO., LTD. 
